Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, M.D., Edith A. Perez, M.D., John Bryant, Ph.D., Vera J. Suman, Ph.D., Charles E. Geyer, Jr., M.D., Nancy E. Davidson, M.D., Elizabeth Tan-Chiu, M.D., Silvana Martino, D.O., Soonmyung Paik, M.D., Peter A. Kaufman, M.D., Sandra M. Swain, M.D., Thomas M. Pisansky, M.D., Louis Fehrenbacher, M.D., Leila A. Kutteh, M.D., Victor G. Vogel, M.D., Daniel W. Visscher, M.D., Greg Yothers, Ph.D., Robert B. Jenkins, M.D., Ph.D., Ann M. Brown, Sc.D., Shaker R. Dakhil, M.D., Eleftherios P. Mamounas, M.D., M.P.H., Wilma L. Lingle, Ph.D., Pamela M. Klein, M.D., James N. Ingle, M.D., and Norman Wolmark, M.D.
Background We present the combined results of two trials thatcompared adjuvant chemotherapy with or without concurrent trastuzumabin women with surgically removed HER2-positive breast cancer.
Methods The National Surgical Adjuvant Breast and Bowel Projecttrial B-31 compared doxorubicin and cyclophosphamide followedby paclitaxel every 3 weeks (group 1) with the same regimenplus 52 weeks of trastuzumab beginning with the first dose ofpaclitaxel (group 2). The North Central Cancer Treatment Grouptrial N9831 compared three regimens: doxorubicin and cyclophosphamidefollowed by weekly paclitaxel (group A), the same regimen followedby 52 weeks of trastuzumab after paclitaxel (group B), and thesame regimen plus 52 weeks of trastuzumab initiated concomitantlywith paclitaxel (group C). The studies were amended to includea joint analysis comparing groups 1 and A (the control group)with groups 2 and C (the trastuzumab group). Group B was excludedbecause trastuzumab was not given concurrently with paclitaxel.
Results By March 15, 2005, 394 events (recurrent, second primarycancer, or death before recurrence) had been reported, triggeringthe first scheduled interim analysis. Of these, 133 were inthe trastuzumab group and 261 in the control group (hazard ratio,0.48; P<0.0001). This result crossed the early stopping boundary.The absolute difference in disease-free survival between thetrastuzumab group and the control group was 12 percent at threeyears. Trastuzumab therapy was associated with a 33 percentreduction in the risk of death (P=0.015). The three-year cumulativeincidence of class III or IV congestive heart failure or deathfrom cardiac causes in the trastuzumab group was 4.1 percentin trial B-31 and 2.9 percent in trial N9831.
Conclusions Trastuzumab combined with paclitaxel after doxorubicinand cyclophosphamide improves outcomes among women with surgicallyremoved HER2-positive breast cancer. (ClinicalTrials.gov numbers,NCT00004067
[ClinicalTrials.gov]
and NCT00005970
[ClinicalTrials.gov]
.)
Source Information
From the National Surgical Adjuvant Breast and Bowel Project, Pittsburgh (E.H.R., J.B., C.E.G., E.T.-C., S.P., S.M.S., L.F., V.G.V., G.Y., A.M.B., E.P.M., N.W.); University of Kentucky, Lexington (E.H.R.); North Central Cancer Treatment Group, Rochester, Minn. (E.A.P., V.J.S., T.M.P., L.A.K., D.W.V., R.B.J., S.R.D., W.L.L., J.N.I.); Mayo Clinic Jacksonville, Jacksonville, Fla. (E.A.P.); University of Pittsburgh, Pittsburgh (J.B., G.Y.); Mayo Clinic, Rochester, Minn. (V.J.S., T.M.P., D.W.V., R.B.J., W.L.L., J.N.I.); Allegheny General Hospital, Pittsburgh (C.E.G., N.W.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (N.E.D.), the Cancer Research Network, Plantation, Fla. (E.T.-C.); Angeles Clinic and Research Institute, Santa Monica, Calif. (S.M.); Norris Cotton Cancer Center, Dartmouth–Hitchcock Medical Center, Lebanon, N.H. (P.A.K.); Cancer Therapeutics Branch, National Cancer Institute, Bethesda, Md. (S.M.S.); Kaiser Permanente Medical Center Northern California, Vallejo (L.F.); Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa (L.A.K.); University of Pittsburgh Cancer Institute, Pittsburgh (V.G.V.); Wichita Community Clinical Oncology Program, Wichita, Kans. (S.R.D.); Aultman Health Foundation, Canton, Ohio (E.P.M.); and Genentech, South San Francisco, Calif. (P.M.K.). Drs. Romond and Perez contributed equally to the article.
Address reprint requests to Dr. Geyer at the Allegheny Cancer Center, 5th Fl., 320 E. North Ave., Pittsburgh, PA 15212, or at cgeyer{at}wpahs.org.
Trastuzumab in Breast Cancer
Gilbert S. G., Banna G. L., Santoro A., Gounaris I. G., Katsumata M., Drebin J. A., Greene M. I., Mastrianni D. M., Mano M., Cameron D., Gelber R. D., the HERA Trial Study Team , Bryant J., Romond E., Perez E. A., Hortobagyi G. N., Barron H.
Extract |
Full Text |
PDF
N Engl J Med 2006;
354:640-644, Feb 9, 2006.
Correspondence
This article has been cited by other articles:
Fojo, T., Grady, C.
(2009). How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI J Natl Cancer Inst
0: djp177v1-5
[Abstract][Full Text]
Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., on behalf of the Australian New Zealand Breast Can,
(2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol
0: mdp202v1-mdp202
[Abstract][Full Text]
Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A., Mehra, R., Laxman, B., Kalyana-Sundaram, S., Lonigro, R. J., Helgeson, B. E., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Hayes, D. F., Lucas, P. C., Varambally, S., Chinnaiyan, A. M.
(2009). AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. USA
106: 10284-10289
[Abstract][Full Text]
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., Viale, G., Gelber, R. D., Piccart-Gebhart, M., Leyland-Jones, B.
(2009). Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. JCO
27: 2962-2969
[Abstract][Full Text]
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H.-J., Panel members,
(2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol
0: mdp322v1-mdp322
[Abstract][Full Text]
Yeh, E. T.H., Bickford, C. L.
(2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.. J Am Coll Cardiol
53: 2231-2247
[Abstract][Full Text]
Takabatake, D., Taira, N., Hara, F., Sien, T., Kiyoto, S., Takashima, S., Aogi, K., Ohsumi, S., Doihara, H., Takashima, S.
(2009). Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients. Jpn J Clin Oncol
0: hyp050v1-hyp050
[Abstract][Full Text]
Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., Marks, L., Davidson, N., Martino, S., Kaufman, P., Kutteh, L., Dakhil, S. R., Perez, E. A.
(2009). Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831. JCO
27: 2638-2644
[Abstract][Full Text]
Onitilo, A. A., Engel, J. M., Greenlee, R. T., Mukesh, B. N.
(2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res
7: 4-13
[Abstract][Full Text]
Buzdar, A. U.
(2009). Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol
20: 993-999
[Abstract][Full Text]
Shimizu, C., Masuda, N., Yoshimura, K., Tsuda, H., Mano, M., Ando, M., Tamura, K., Fujiwara, Y.
(2009). Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer. Jpn J Clin Oncol
0: hyp052v1-hyp052
[Abstract][Full Text]
Quaye, L., Dafou, D., Ramus, S. J., Song, H., Maharaj, A. G., Notaridou, M., Hogdall, E., Kjaer, S. K., Christensen, L., Hogdall, C., Easton, D. F., Jacobs, I., Menon, U., Pharoah, P. D.P., Gayther, S. A.
(2009). Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet
18: 1869-1878
[Abstract][Full Text]
Hennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., Liu, W., Stivers, D., Baggerly, K., Carey, M., Lluch, A., Monteagudo, C., He, X., Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G. N., Nolden, L. K., Wang, N. J., Valero, V., Gray, J. W., Perou, C. M., Mills, G. B.
(2009). Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res.
69: 4116-4124
[Abstract][Full Text]
Baar, J., Silverman, P., Lyons, J., Fu, P., Abdul-Karim, F., Ziats, N., Wasman, J., Hartman, P., Jesberger, J., Dumadag, L., Hohler, E., Leeming, R., Shenk, R., Chen, H., McCrae, K., Dowlati, A., Remick, S. C., Overmoyer, B.
(2009). A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers. Clin. Cancer Res.
15: 3583-3590
[Abstract][Full Text]
Rickman, O. B., Vohra, P. K., Sanyal, B., Vrana, J. A., Aubry, M.-C., Wigle, D. A., Thomas, C. F. Jr.
(2009). Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors. Clin. Cancer Res.
15: 3315-3324
[Abstract][Full Text]
Shulman, L. N., Jacobs, L. A., Greenfield, S., Jones, B., McCabe, M. S., Syrjala, K., Diller, L., Shapiro, C. L., Marcus, A. C., Campbell, M., Santacroce, S., Kagawa-Singer, M., Ganz, P. A.
(2009). Cancer Care and Cancer Survivorship Care in the United States: Will We Be Able to Care for These Patients in the Future?. J Oncol Pract
5: 119-123
[Abstract][Full Text]
Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., Stathopoulos, E. N., Chlouverakis, G., Lianidou, E., Kakolyris, S., Georgoulias, V., Mavroudis, D.
(2009). Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. JCO
27: 2177-2184
[Abstract][Full Text]
Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C. J., Stanley, A., Verrill, M. W.
(2009). Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol
20: 816-827
[Abstract][Full Text]
BROOM, R. J., TANG, P. A., SIMMONS, C., BORDELEAU, L., MULLIGAN, A. M., O'MALLEY, F. P., MILLER, N., ANDRULIS, I. L., BRENNER, D. M., CLEMONS, M. J.
(2009). Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer. Anticancer Res
29: 1557-1562
[Abstract][Full Text]
Contractor, K. B., Aboagye, E. O.
(2009). Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET. JNM
50: 97S-105S
[Abstract][Full Text]
Kataja, V., Castiglione, M., On behalf of the ESMO Guidelines Working Group,
(2009). Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol
20: iv10-iv14
[Full Text]
Borczuk, A. C., Toonkel, R. L., Powell, C. A.
(2009). Genomics of Lung Cancer. Proc Am Thorac Soc
6: 152-158
[Abstract][Full Text]
Sparano, J. A., Moulder, S., Kazi, A., Coppola, D., Negassa, A., Vahdat, L., Li, T., Pellegrino, C., Fineberg, S., Munster, P., Malafa, M., Lee, D., Hoschander, S., Hopkins, U., Hershman, D., Wright, J. J., Kleer, C., Merajver, S., Sebti, S. M.
(2009). Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. Clin. Cancer Res.
15: 2942-2948
[Abstract][Full Text]
Gong, Y., Sweet, W., Duh, Y.-J., Greenfield, L., Fang, Y., Zhao, J., Tarco, E., Symmans, W. F., Isola, J., Sneige, N.
(2009). Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations. Am J Clin Pathol
131: 490-497
[Abstract][Full Text]
Korn, E. L., Freidlin, B., Mooney, M.
(2009). Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005. JCO
27: 1712-1721
[Abstract][Full Text]
Sargent, D.
(2009). Early Stopping for Benefit in National Cancer Institute-Sponsored Randomized Phase III Trials: The System Is Working. JCO
27: 1543-1544
[Full Text]
Lennon, S., Barton, C., Banken, L., Gianni, L., Marty, M., Baselga, J., Leyland-Jones, B.
(2009). Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer. JCO
27: 1685-1693
[Abstract][Full Text]
Leary, A. F., Hanna, W. M., van de Vijver, M. J., Penault-Llorca, F., Ruschoff, J., Osamura, R. Y., Bilous, M., Dowsett, M.
(2009). Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients. JCO
27: 1694-1705
[Abstract][Full Text]
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., Malone, K. E.
(2009). Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiol. Biomarkers Prev.
18: 1157-1166
[Abstract][Full Text]
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N.
(2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist
14: 320-368
[Abstract][Full Text]
Houshmandi, S. S., Emnett, R. J., Giovannini, M., Gutmann, D. H.
(2009). The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner. Mol. Cell. Biol.
29: 1472-1486
[Abstract][Full Text]
Ignatiadis, M., Desmedt, C., Sotiriou, C., de Azambuja, E., Piccart, M.
(2009). HER-2 as a Target for Breast Cancer Therapy. Clin. Cancer Res.
15: 1848-1852
[Full Text]
Sauter, G., Lee, J., Bartlett, J. M.S., Slamon, D. J., Press, M. F.
(2009). Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. JCO
27: 1323-1333
[Abstract][Full Text]
Stokoe, C.
(2009). Adapting Practice in the Face of New Data. J Oncol Pract
5: 83-85
[Full Text]
Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L., Wang, A., Eisenberg, M., Rowland, C. M., Hessling, J. J., Broder, S. E., Sninsky, J. J., Tutt, A., Anderson, S., Chang, S.-Y. P.
(2009). A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. J. Mol. Diagn.
11: 117-130
[Abstract][Full Text]
Anton, A., Ruiz, A., Segui, M. A., Calvo, L., Munoz, M., Lao, J., Sancho, F., Fernandez, L.
(2009). Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol
20: 454-459
[Abstract][Full Text]
MIYAMOTO, S., FUKAMI, T., YAGI, H., KUROKI, M., YOTSUMOTO, F.
(2009). Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands. Anticancer Res
29: 823-830
[Abstract][Full Text]
Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., Seitz, J. F., Francini, G., Haller, D., Yothers, G., Goldberg, R., de Gramont, A.
(2009). Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. JCO
27: 872-877
[Abstract][Full Text]
Russell, N. S., Kunkler, I. H., van Tienhoven, G., Canney, P. A., Thomas, J., Bartlett, J., van de Vijver, M. J., Belkacemi, Y., Yarnold, J. R., Barrett-Lee, P. J.
(2009). Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. JCO
27: 996-997
[Full Text]
Partridge, A. H., Winer, E. P.
(2009). Sharing Study Results With Trial Participants: Time for Action. JCO
27: 838-839
[Full Text]
Choi, Y. H., Ahn, J. H., Kim, S.-B., Jung, K.-H., Gong, G.-Y., Kim, M.-J., Son, B.-H., Ahn, S.-H., Kim, W. K.
(2009). Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol
0: mdp003v1-mdp003
[Abstract][Full Text]
Dawood, S., Broglio, K., Kau, S.-W., Green, M. C., Giordano, S. H., Meric-Bernstam, F., Buchholz, T. A., Albarracin, C., Yang, W. T., Hennessy, B. T.J., Hortobagyi, G. N., Gonzalez-Angulo, A. M.
(2009). Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. JCO
27: 220-226
[Abstract][Full Text]
Sinclair, S., Zimmer, A. S., Swain, S. M.
(2009). HER-2 Targeting Agents and Antiangiogenic Therapy: Evolution of Adjuvant Therapy in Breast Cancer. Am Soc Clin Oncol Ed Book
2009: 3-10
[Abstract][Full Text]
Coxon, A., Bush, T., Saffran, D., Kaufman, S., Belmontes, B., Rex, K., Hughes, P., Caenepeel, S., Rottman, J. B., Tasker, A., Patel, V., Kendall, R., Radinsky, R., Polverino, A.
(2009). Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clin. Cancer Res.
15: 110-118
[Abstract][Full Text]
Cortes, J., Di Cosimo, S., Climent, M. A., Cortes-Funes, H., Lluch, A., Gascon, P., Mayordomo, J. I., Gil, M., Benavides, M., Cirera, L., Ojeda, B., Rodriguez, C. A., Trigo, J. M., Vazquez, J., Regueiro, P., Dorado, J. F., Baselga, J., on behalf of the Spanish Breast Cancer Cooperative,
(2009). Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clin. Cancer Res.
15: 307-314
[Abstract][Full Text]
Morris, P. G., McArthur, H. L., Dang, C. T., Hudis, C. A.
(2009). Selection of Appropriate Patients for Anthracycline Therapy. Am Soc Clin Oncol Ed Book
2009: 11-18
[Abstract][Full Text]
Martin, M., Esteva, F. J., Alba, E., Khandheria, B., Perez-Isla, L., Garcia-Saenz, J. A., Marquez, A., Sengupta, P., Zamorano, J.
(2009). Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. The Oncologist
14: 1-11
[Abstract][Full Text]
Peppercorn, J., Burstein, H., Miller, F. G., Winer, E., Joffe, S.
(2008). Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy. JCO
26: 5994-6000
[Abstract][Full Text]
Dowsett, M., Dunbier, A. K.
(2008). Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. Clin. Cancer Res.
14: 8019-8026
[Abstract][Full Text]
Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., Gelmon, K.
(2008). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. JCO
26: 5697-5704
[Abstract][Full Text]
Ziogas, D., Ignatiadou, E., Roukos, D., Lykoudis, E.
(2008). HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer. Ann. Surg. Oncol.
15: 3614-3615
[Full Text]
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P.
(2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem.
54: e11-e79
[Abstract][Full Text]
Peintinger, F., Buzdar, A. U., Kuerer, H. M., Mejia, J. A., Hatzis, C., Gonzalez-Angulo, A. M., Pusztai, L., Esteva, F. J., Dawood, S. S., Green, M. C., Hortobagyi, G. N., Symmans, W. F.
(2008). Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol
19: 2020-2025
[Abstract][Full Text]
Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J., Yeh, B., Lake, D. E., Dang, C. T., Gilewski, T. A., Bromberg, J. F., Seidman, A. D., D'Andrea, G. M., Moasser, M. M., Melisko, M., Park, J. W., Dancey, J., Norton, L., Hudis, C. A.
(2008). A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clin. Cancer Res.
14: 7878-7883
[Abstract][Full Text]
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V.J., Lutz, R. J., Wong, W. L. T., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., Sliwkowski, M. X.
(2008). Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Res.
68: 9280-9290
[Abstract][Full Text]
So, A. I., Levitt, R. J., Eigl, B., Fazli, L., Muramaki, M., Leung, S., Cheang, M. C.U., Nielsen, T. O., Gleave, M., Pollak, M.
(2008). Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. Clin. Cancer Res.
14: 6944-6954
[Abstract][Full Text]
Berruti, A., Brizzi, M. P., Generali, D., Ardine, M., Dogliotti, L., Bruzzi, P., Bottini, A.
(2008). Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions. The Oncologist
13: 1137-1148
[Abstract][Full Text]
Stagg, J., Sharkey, J., Pommey, S., Young, R., Takeda, K., Yagita, H., Johnstone, R. W., Smyth, M. J.
(2008). Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc. Natl. Acad. Sci. USA
105: 16254-16259
[Abstract][Full Text]
Dawood, S., Broglio, K., Gonzalez-Angulo, A. M., Buzdar, A. U., Hortobagyi, G. N., Giordano, S. H.
(2008). Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer. JCO
26: 4891-4898
[Abstract][Full Text]
Vanden Bempt, I., Van Loo, P., Drijkoningen, M., Neven, P., Smeets, A., Christiaens, M.-R., Paridaens, R., De Wolf-Peeters, C.
(2008). Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing. JCO
26: 4869-4874
[Abstract][Full Text]
Sarup, J., Jin, P., Turin, L., Bai, X., Beryt, M., Brdlik, C., Higaki, J. N., Jorgensen, B., Lau, F. W., Lindley, P., Liu, J., Ni, I., Rozzelle, J., Kumari, R., Watson, S. A., Zhang, J., Shepard, H. M.
(2008). Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Molecular Cancer Therapeutics
7: 3223-3236
[Abstract][Full Text]
Menard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M. L., Gloghini, A., Scalone, S., Querzoli, P., Lunardi, M., Molino, A., Mandara, M., Mottolese, M., Marandino, F., Venturini, M., Bighin, C., Cancello, G., Montagna, E., Perrone, F., De Matteis, A., Sapino, A., Donadio, M., Battelli, N., Santinelli, A., Pavesi, L., Lanza, A., Zito, F. A., Labriola, A., Aiello, R. A., Caruso, M., Zanconati, F., Mustacchi, G., Barbareschi, M., Frisinghelli, M., Russo, R., Carrillo, G., On the behalf of the OMERO group,
(2008). Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol
19: 1706-1712
[Abstract][Full Text]
Mehta, R. S., Schubbert, T., Kong, K.
(2008). Trastuzumab in inflammatory breast cancer. Ann Oncol
19: 1815-1817
[Full Text]
Arteaga, C. L., O'Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., Davidson, N. E.
(2008). A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clin. Cancer Res.
14: 6277-6283
[Abstract][Full Text]
Srinivasan, S., Parsa, V., Liu, C. Y, Fontana, J. A
(2008). Trastuzumab-Induced Hepatotoxicity. The Annals of Pharmacotherapy
42: 1497-1501
[Abstract][Full Text]
Whittington, P. J., Piechocki, M. P., Heng, H. H., Jacob, J. B., Jones, R. F., Back, J. B., Wei, W.-Z.
(2008). DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies. Cancer Res.
68: 7502-7511
[Abstract][Full Text]
Roukos, D. H., Lykoudis, E., Liakakos, T.
(2008). Genomics and Challenges Toward Personalized Breast Cancer Local Control. JCO
26: 4360-4361
[Full Text]
Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., Sledge, G. W. Jr, Perez, E. A., Shulman, L. N., Martino, S., Sparano, J. A.
(2008). Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. JCO
26: 4063-4071
[Abstract][Full Text]
King, J., Waxman, J., Stauss, H.
(2008). Advances in tumour immunotherapy. QJM
101: 675-683
[Abstract][Full Text]
Rayson, D., Richel, D., Chia, S., Jackisch, C., van der Vegt, S., Suter, T.
(2008). Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol
19: 1530-1539
[Abstract][Full Text]
Hines, S. L., Vallow, L. A., Tan, W. W., McNeil, R. B., Perez, E. A., Jain, A.
(2008). Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol
19: 1561-1565
[Abstract][Full Text]
Anderson, J. R., Cain, K. C., Gelber, R. D.
(2008). Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables. JCO
26: 3913-3915
[Full Text]
Alix-Panabieres, C., Riethdorf, S., Pantel, K.
(2008). Circulating Tumor Cells and Bone Marrow Micrometastasis. Clin. Cancer Res.
14: 5013-5021
[Abstract][Full Text]
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., Steeg, P. S.
(2008). Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI J Natl Cancer Inst
100: 1092-1103
[Abstract][Full Text]
Nunes, C B, Rocha, R M, Reis-Filho, J S, Lambros, M B, Rocha, G F S, Sanches, F S F, Oliveira, F N, Gobbi, H
(2008). Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J. Clin. Pathol.
61: 934-938
[Abstract][Full Text]
Lee, T. H., Emanuel, E. J.
(2008). Tier 4 Drugs and the Fraying of the Social Compact. NEJM
359: 333-335
[Full Text]
Dang, C., Norton, L., Hudis, C.
(2008). Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option. JCO
26: 3655-3656
[Full Text]
Turner, N. C, Jones, A. L
(2008). Management of breast cancer--Part II. BMJ
337: a540-a540
[Full Text]
Peppercorn, J., Partridge, A. H.
(2008). Breast Cancer in Young Women: A New Color or a Different Shade of Pink?. JCO
26: 3303-3305
[Full Text]
Rowe, D. L., Ozbay, T., Bender, L. M., Nahta, R.
(2008). Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Molecular Cancer Therapeutics
7: 1900-1908
[Abstract][Full Text]
Trotta, F., Apolone, G., Garattini, S., Tafuri, G.
(2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol
19: 1347-1353
[Abstract][Full Text]
Walker, R A, Bartlett, J M S, Dowsett, M, Ellis, I O, Hanby, A M, Jasani, B, Miller, K, Pinder, S E
(2008). HER2 testing in the UK: further update to recommendations. J. Clin. Pathol.
61: 818-824
[Abstract][Full Text]
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W.C., Arbushites, M. C., Casey, M. A., Berger, M. S., Stein, S. H., Sledge, G. W.
(2008). Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. JCO
26: 2999-3005
[Abstract][Full Text]
Conrad, H., Gebhard, K., Kronig, H., Neudorfer, J., Busch, D. H., Peschel, C., Bernhard, H.
(2008). CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4. J. Immunol.
180: 8135-8145
[Abstract][Full Text]
Hudis, C., Dang, C.
(2008). The Taxane Limbo: How Low Can We Go?. JNCI J Natl Cancer Inst
100: 761-763
[Full Text]
Mayer, M.
(2008). Swimming Upstream: An Advocate Reflects on Cancer Research and Social Realities. JCO
26: 2783-2786
[Full Text]
MacKenzie, R., Chapman, S., Salkeld, G., Holding, S.
(2008). Media influence on Herceptin subsidization in Australia: application of the rule of rescue?. JRSM
101: 305-312
[Abstract][Full Text]
Kulkarni, S., Hicks, D. G.
(2008). HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective. Ann. Surg. Oncol.
15: 1677-1688
[Abstract][Full Text]
Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J. I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. S., Srimuninnimit, V., Colleoni, M., Coates, A. S., Piccart-Gebhart, M. J., Goldhirsch, A., for the HERA Study Team,
(2008). Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol
19: 1090-1096
[Abstract][Full Text]
Belkacemi, Y., Gligorov, J., Ozsahin, M., Marsiglia, H., De Lafontan, B., Laharie-Mineur, H., Aimard, L., Antoine, E.-C., Cutuli, B., Namer, M., Azria, D.
(2008). Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol
19: 1110-1116
[Abstract][Full Text]
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., Ewer, M. S.
(2008). Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clin Proc.
83: 679-686
[Abstract][Full Text]
Previous
